Lenalidomide-induced acute acneiform folliculitis of the head and neck: not only the anti-EGF receptor agents.
Michot
Carine
C
Guillot
Bernard
B
Dereure
Olivier
O
D017486:Acneiform Eruptions / Q000175:diagnosis / Q000276:immunology / Q000382:microbiology; D000368:Aged; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D002176:Candida albicans; D002177:Candidiasis / Q000276:immunology* / Q000382:microbiology / Q000473:pathology; D003898:Desonide / Q000627:therapeutic use; D003907:Dexamethasone / Q000009:adverse effects / Q000627:therapeutic use; D004318:Doxycycline / Q000627:therapeutic use; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D015725:Fluconazole / Q000627:therapeutic use; D005499:Folliculitis / Q000276:immunology* / Q000382:microbiology / Q000473:pathology; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects* / Q000627:therapeutic use; D000077269:Lenalidomide; D008297:Male; D009101:Multiple Myeloma / Q000188:drug therapy*; D011719:Pyrazines / Q000627:therapeutic use; D013792:Thalidomide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D001897:Boronic Acids; D007155:Immunologic Factors; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D003907:Dexamethasone; D015725:Fluconazole; D066246:ErbB Receptors; D000077269:Lenalidomide; D003898:Desonide; D004318:Doxycycline